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Abstract

Discussion

• Major depressive disorder (MDD) is one of the most prevalent
psychiatric disorders in the United States and is a large cause of
disability. Antidepressants take weeks/months to become effective which
can lead to noncompliance. Treatment has a high failure rate which
increases medical costs and leads to decreased patient outcomes.

In summary this research found
• Pharmacogenomic-guided treatment has shown effectiveness and
improved patient outcomes when compared to the current standard
of treatment.
• The utility of this genetic information as it pertains to clinical
decision making, treatment effectiveness, and cost savings has
shown benefit for patients with moderate to severe depression who
have failed prior treatment.
• Pharmacogenetic testing provides significant cost savings, while
simultaneously improving adherence in a difficult to treat
psychiatric population. Patients who had pharmacogenetic-guided
treatment had improved outcomes in addition to decreased cost to
the patient by having fewer clinic visits, less changes in
prescriptions, lessened and shorter sick leave taken, and decreased
hospital costs.

• Pharmacogenetic testing is the practice of analyzing genetic differences
to predict a patient’s response to medications to improve efficacy and
decrease adverse side effects. The purpose of this study was to
investigate if pharmacogenetic-guided treatment, specifically in the use
of antidepressants in MDD, has resulted in improved patient outcomes.
Additionally, the cost effectiveness was also analyzed.
• The review of literature was conducted by systematically searching the
online databases PubMed and PsycINFO, and explored studies that
compared the current standard of care to pharmacogenetic-guided
treatment in adult patients with MDD aged 18-75.
• The results indicated improved compliance and prognosis for patients
with MDD using pharmacogenetic-guided treatment versus the current
standard of care. Studies also showed cost effectiveness of
pharmacogenetic-guided treatment by decreasing medical costs by
having fewer clinic visits, less changes in prescriptions, less sick leave
taken, and decreased hospital costs.

Introduction
• There is variability in the pathophysiology of depression and not all
details are known. Despite recent advances in the use of
antidepressants, interindividual variability to treatment remains a serious
problem. As patients continue to fail medication regimens, the likelihood
of responding to subsequent treatment decreases to 18%. Furthermore,
depression has one of the highest instances of mortality from suicide.
• Pharmacogenetic testing has been developed to test a set of preselected
psychiatric genes to provide a composite phenotype and accompanying
interpretative report. By predicting the drug response of an individual, it
may be possible to increase the success rate of antidepressant use and
reduce the incidence of adverse side effects.

Statement of the Problem
Major depressive disorder is associated with a high prevalence of
therapeutic failure, adverse side effects from medications, and a high
recurrence rate. Response to antidepressants take an extended length of
time which leads to noncompliance and increased medical costs due to
additional follow-up visits and prescription costs.

Research Questions
• In adult patients with a diagnosis of major depressive disorder,
does utilizing pharmacogenetic testing to determine
antidepressant use result in improved patient outcomes?
• Is pharmacogenetic testing for the patient with major depressive
disorder cost effective?

Applicability to Clinical Practice

Figure 1.
Figure 1. GeneSight integrative methodology. (Winner, 2013)

• As a newer topic in the medical field, efforts are needed to improve
clinicians’ knowledge of pharmacogenetic testing in order to facilitate its
successful integration into clinical practice.
• Pharmacogenetic testing can aid in directing treatment towards a more
effective approach.
• Medicare Part B and Veterans Affairs cover pharmacogenetic testing if
deemed medically necessary.
• Pharmacogenetic testing is a relatively new concept, but has been proven
to have advantages over the current treatment of MDD. It offers providers
an effective resource to provide improved outcomes for patients with MDD
requiring pharmacotherapy.

Literature Review
• Altar et al. (2015) found subjects who entered the study on red
category medications showed 61.5% less improvement in
depressive symptoms over 8–10 weeks compared with those
prescribed yellow (t = 3.15; P = 0.002), green (t = 2.22, P = 0.02) or
yellow ± green category medications (t = 2.97, P = 0.003).
• Hall-Flavin et al. (2013) found the pharmacogenetic guided group
experienced greater percent improvement in depression scores
from baseline on three depression instruments (HAMD-17, P <
0.0001; QIDS-C16, P < 0.0001; PHQ-9, P < 0.0001) compared with
the unguided group. Using repeated measures analysis for all
participants who completed the 8-week study, a greater reduction
of symptoms was observed for guided group participants compared
with unguided group participants for HAMD-17 (P < 0.001), QIDSC16 (P < 0.001), and PHQ-9 (P = 0.002) (Figure 2). Significantly
greater response rates (i.e. >50% reduction in score from baseline)
were found in the guided group versus the unguided group at week
8 as determined with QIDS-C16; 44.4% of participants in the
guided group responded versus 23.7% in the unguided group.
HAMD-17 and PHQ-9 showed nearly identical results.
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• Winner et al. (2013) determined that the likelihood of response and
remission was greater than double in the GeneSight guided group
measured by HAMD-17 at week 10. Mean percent improvement in
symptoms on HAMD-17 was higher for the GeneSight group over
treatment as usual (30.8% vs 20.7%; p=0.28).
• Singh (2015) found that subjects receiving genetically guided
prescribing had a 2.52-fold greater chance of remission (p<0.0001).
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Figure 2. Repeated measures analysis by depression scale. (Hall-Flavin, 2013)

